Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 296

1.

Risk of acute myocardial infarction, stroke, heart failure, and death in elderly Medicare patients treated with rosiglitazone or pioglitazone.

Graham DJ, Ouellet-Hellstrom R, MaCurdy TE, Ali F, Sholley C, Worrall C, Kelman JA.

JAMA. 2010 Jul 28;304(4):411-8. doi: 10.1001/jama.2010.920. Epub 2010 Jun 28.

PMID:
20584880
2.

Risk of stroke with thiazolidinediones: a ten-year nationwide population-based cohort study.

Lu CJ, Sun Y, Muo CH, Chen RC, Chen PC, Hsu CY.

Cerebrovasc Dis. 2013;36(2):145-51. doi: 10.1159/000353679. Epub 2013 Sep 11.

PMID:
24029780
3.

Rosiglitazone and outcomes for patients with diabetes mellitus and coronary artery disease in the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) trial.

Bach RG, Brooks MM, Lombardero M, Genuth S, Donner TW, Garber A, Kennedy L, Monrad ES, Pop-Busui R, Kelsey SF, Frye RL; BARI 2D Investigators.

Circulation. 2013 Aug 20;128(8):785-94. doi: 10.1161/CIRCULATIONAHA.112.000678. Epub 2013 Jul 15.

4.

Adverse cardiovascular events during treatment with pioglitazone and rosiglitazone: population based cohort study.

Juurlink DN, Gomes T, Lipscombe LL, Austin PC, Hux JE, Mamdani MM.

BMJ. 2009 Aug 18;339:b2942. doi: 10.1136/bmj.b2942.

5.

The thiazolidinediones rosiglitazone and pioglitazone and the risk of coronary heart disease: a retrospective cohort study using a US health insurance database.

Ziyadeh N, McAfee AT, Koro C, Landon J, Arnold Chan K.

Clin Ther. 2009 Nov;31(11):2665-77. doi: 10.1016/j.clinthera.2009.11.003.

PMID:
20110009
6.

Thiazolidinediones and cardiovascular outcomes in older patients with diabetes.

Lipscombe LL, Gomes T, Lévesque LE, Hux JE, Juurlink DN, Alter DA.

JAMA. 2007 Dec 12;298(22):2634-43.

PMID:
18073359
7.

Comparison of cardiovascular outcomes in elderly patients with diabetes who initiated rosiglitazone vs pioglitazone therapy.

Winkelmayer WC, Setoguchi S, Levin R, Solomon DH.

Arch Intern Med. 2008 Nov 24;168(21):2368-75. doi: 10.1001/archinte.168.21.2368.

PMID:
19029503
8.

Incidence of cardiovascular events in which 2 thiazolidinediones are used as add-on treatments for type 2 diabetes mellitus in a Taiwanese population.

Wang CC, Chen WL, Kao TW, Chang YW, Loh CH, Chou CC.

Clin Ther. 2011 Dec;33(12):1904-13. doi: 10.1016/j.clinthera.2011.10.025. Epub 2011 Nov 25. Erratum in: Clin Ther. 2012 Feb;34(2):508. Chou, Chih-Chieh [corrected to Chou, Chin-Chieh].

PMID:
22118894
9.

Development of heart failure in Medicaid patients with type 2 diabetes treated with pioglitazone, rosiglitazone, or metformin.

Breunig IM, Shaya FT, McPherson ML, Snitker S.

J Manag Care Spec Pharm. 2014 Sep;20(9):895-903.

10.

Comparative cardiovascular effects of thiazolidinediones: systematic review and meta-analysis of observational studies.

Loke YK, Kwok CS, Singh S.

BMJ. 2011 Mar 17;342:d1309. doi: 10.1136/bmj.d1309. Review.

11.

Comparing pioglitazone to insulin with respect to cancer, cardiovascular and bone fracture endpoints, using propensity score weights.

Vallarino C, Perez A, Fusco G, Liang H, Bron M, Manne S, Joseph G, Yu S.

Clin Drug Investig. 2013 Sep;33(9):621-31. doi: 10.1007/s40261-013-0106-9.

12.

Relationship between thiazolidinedione use and cardiovascular outcomes and all-cause mortality among patients with diabetes: a time-updated propensity analysis.

Habib ZA, Tzogias L, Havstad SL, Wells K, Divine G, Lanfear DE, Tang J, Krajenta R, Pladevall M, Williams LK.

Pharmacoepidemiol Drug Saf. 2009 Jun;18(6):437-47. doi: 10.1002/pds.1722.

13.

A comparison of pioglitazone and rosiglitazone for hospitalization for acute myocardial infarction in type 2 diabetes.

Gerrits CM, Bhattacharya M, Manthena S, Baran R, Perez A, Kupfer S.

Pharmacoepidemiol Drug Saf. 2007 Oct;16(10):1065-71.

PMID:
17674425
14.

Rosiglitazone and pioglitazone utilization from January 2007 through May 2008 associated with five risk-warning events.

Starner CI, Schafer JA, Heaton AH, Gleason PP.

J Manag Care Pharm. 2008 Jul-Aug;14(6):523-31.

15.
16.
17.

Risk of acute myocardial infarction in patients treated with thiazolidinediones or other antidiabetic medications.

Stockl KM, Le L, Zhang S, Harada AS.

Pharmacoepidemiol Drug Saf. 2009 Feb;18(2):166-74. doi: 10.1002/pds.1700.

PMID:
19109802
18.

Incidence rates of heart failure, stroke, and acute myocardial infarction among Type 2 diabetic patients using insulin glargine and other insulin.

Juhaeri J, Gao S, Dai WS.

Pharmacoepidemiol Drug Saf. 2009 Jun;18(6):497-503. doi: 10.1002/pds.1741.

PMID:
19326365
19.

Risk of cardiovascular disease and all cause mortality among patients with type 2 diabetes prescribed oral antidiabetes drugs: retrospective cohort study using UK general practice research database.

Tzoulaki I, Molokhia M, Curcin V, Little MP, Millett CJ, Ng A, Hughes RI, Khunti K, Wilkins MR, Majeed A, Elliott P.

BMJ. 2009 Dec 3;339:b4731. doi: 10.1136/bmj.b4731.

20.

Database evaluation of the effects of long-term rosiglitazone treatment on cardiovascular outcomes in patients with type 2 diabetes.

Loebstein R, Dushinat M, Vesterman-Landes J, Silverman B, Friedman N, Katzir I, Kurnik D, Lomnicky Y, Kokia E, Halkin H.

J Clin Pharmacol. 2011 Feb;51(2):173-80. doi: 10.1177/0091270010368281. Epub 2010 May 19.

PMID:
20484611

Supplemental Content

Support Center